Background
Methods
Literature search
Criteria for inclusion and exclusion
Quality assessment
Data extraction
Statistical analysis
Results
Selection of included articles
Characteristics and quality assessment of studies
References | Year | Country | No. of patients | Gender (M/F, n) | Age range (years) | Method | Antibody dilution | Counting method | Cut-off staining | Reduced Beclin-1 expression (%) | OS data provided |
---|---|---|---|---|---|---|---|---|---|---|---|
Ding [15] | 2008 | China | 300 | 252/48 | NR | IHC | 1:50 | IRS* | 10% | 205/300 (68.33) | Yes |
Kang [21] | 2013 | China | 50 | 47/3 | 28–71 | IHC | NR | IRS | 4 | 11/50 (22.00) | No |
Lee [22] | 2013 | Korea | 190 | 158/32 | 29–76 | IHC | NR | IRS | 6 | 179/190 (94.21) | Yes |
Guo [26] | 2013 | China | 54 | 39/15 | 33–75 | IHC | 1:150 | IRS | 3 | 10/54 (18.52) | No |
Qiu [14] | 2014 | China | 103 | 85/18 | 21–79 | IHC | 1:100 | IRS | 8 | 81/103 (78.64) | Yes |
Wu [16] | 2014 | China | 156 | 143/13 | NR | IHC | 1:100 | IRS | 6 | 83/156 (53.21) | Yes |
Osman [23] | 2015 | Egypt | 65 | 51/14 | 40–74 | IHC | 1:100 | IRS* | 10% | 32/65 (49.23) | No |
Yang [27] | 2015 | China | 50 | 39/11 | 26–74 | IHC | NR | IRS | 3 | 11/50 (22.00) | No |
Al-Shenawy [24] | 2016 | Egypt | 35 | 20/15 | 23–75 | IHC | 1:350 | IRS | 1 | 18/35 (51.43) | No |
Zhou [25] | 2016 | China | 83 | 69/14 | NR | IHC | 1:100 | NR | NR | 45/83 (54.22) | Yes |
Study | Selection | Comparability | Outcome | Total | |||||
---|---|---|---|---|---|---|---|---|---|
Exposed cohort | Non-exposed cohort | Ascertainment of exposure | Outcome of interest | Control for factor | Assessment of outcome | Follow-up long enough | Adequacy of follow-up | score | |
Ding [15] | * | * | * | * | ** | * | * | * | 9 |
Kang [21] | * | * | * | * | * | * | * | * | 8 |
Lee [22] | * | * | * | * | ** | * | * | 8 | |
Guo [26] | * | * | * | * | ** | * | * | * | 9 |
Qiu [14] | * | * | * | * | ** | * | * | * | 9 |
Wu [16] | * | * | * | * | ** | * | * | * | 9 |
Osman [23] | * | * | * | * | * | * | * | * | 8 |
Yang [27] | * | * | * | * | ** | * | * | * | 9 |
Al-Shenawy [24] | * | * | * | * | ** | * | * | * | 9 |
Zhou [25] | * | * | * | * | * | * | 6 |
Beclin-1 expression and clinicopathological parameters
Beclin-1 expression and OS
Sensitivity analysis
Subgroup analysis
Subgroups | No. of studies | Pooled OR (95% CI) | P value | Heterogeneity | |
---|---|---|---|---|---|
I
2
| P value | ||||
Liver cirrhosis | |||||
Asia | 6 | 1.27 (0.72–2.25) | 0.42 | 42% | 0.12 |
Egypt | 2 | 10.03 (0.74–136.23) | 0.08 | 63% | 0.10 |
HBsAg | |||||
Asia | 6 | 0.91 (0.61–1.34) | 0.62 | 38% | 0.15 |
Egypt | 1 | 0.24 (0.06–0.97) | 0.04 | – | – |